Year: 2013
Type: article
Abstract: Since the first reports of its efficacy for myeloma in the early 1960s [1-3], melphalan has remained a key component of the oncologist’s armamentarium. High-dose melphalan therapy was introduced in the early 1980s [4] and has since been employed with stem cell rescue for “younger” myeloma patients, with the age limit now pushing 75 years with advances in supportive care measures [5]. The era of novel drug development has reawakened the debate of whether or not to approach the disease with a curative intent [6].
Author: Saad Z. Usmani
Institution: University of Arkansas for Medical Sciences
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
Funder: Celgene
OpenAlex ID: W1980694501